Alecensa
Alecensa is an oral treatment for adults with ALK+ non-small cell lung cancer (NSCLC).
Last updated September 11, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Alecensa is an oral treatment for adults with non-small cell lung cancer (NSCLC) caused by an abnormal ALK gene. It can be used after surgery to help lower the chance of the cancer coming back, or as treatment if the cancer has already spread to other parts of the body. It is taken twice daily with food; the standard dose is four 150-mg capsules (600 mg) per dose, for a total of 1200 mg (eight capsules) per day.
Recent events
Reported
Morocco approves price reductions for medicines[3]
Morocco approved price reductions for 22 pharmaceutical presentations across eight medicine brands under a ministerial order signed on September 22. The changes include price cuts for Alecensa, Avastin, Actemra, Advagraf, Crestor, Apxia and Bestor.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/alecensa · Editorial policy · How profiles are compiled